Novo Nordisk A/S - share repurchase programme
11 März 2024 - 1:46PM
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 11 March 2024 – On 6
February 2024, Novo Nordisk initiated a share repurchase programme
in accordance with Article 5 of Regulation No 596/2014 of the
European Parliament and Council of 16 April 2014 (MAR) and the
Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the
"Safe Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 20 billion to be executed during
a 12-month period beginning 6 February 2023.
Under the programme initiated 6 February 2024, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.1 billion in the
period from 6 February 2024 to 30 April 2024.
Since the announcement 04 March 2024, the following transactions
have been made:
|
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
|
Accumulated, last announcement |
824,500 |
|
689,940,585 |
| 4 March
2024 |
43,500 |
874.36 |
38,034,510 |
| 5 March
2024 |
41,500 |
868.24 |
36,032,046 |
| 6 March
2024 |
41,500 |
847.71 |
35,179,962 |
| 7 March
2024 |
40,500 |
898.67 |
36,395,949 |
|
8 March 2024 |
40,000 |
911.03 |
36,441,191 |
|
Accumulated under the programme |
1,031,500 |
|
872,024,243 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
47,572,207 B shares of DKK 0.10 as treasury shares, corresponding
to 1.1% of the share capital. The total amount of A and B shares in
the company is 4,510,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 6 February 2024.
As of 08 March 2024, Novo Nordisk has since 6 February 2024
repurchased a total of 1,031,500 B shares at an average share price
of DKK 845.39 per B share equal to a transaction value of DKK
872,024,243.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contact for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Company announcement No 22 / 2024
- CA240311 Share-repurchase
- 240311 Transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
